QUIT · Achieve Life Sciences

The thesis

AchieveRx's smoking-cessation drug, cytisinicline, can still reach FDA approval by mid-2027, and the shares are modestly more likely than not to beat the S&P 500 over the next three months if the refiling lands on schedule. A new drug application (NDA) resubmission naming Adare Pharma Solutions as finished-product manufacturer, planned for the fourth quarter of 2026, decides the case.

The FDA rejected the drug on 20 June 2026 over a former manufacturer's plant and incomplete labeling; the company says the agency identified no efficacy or safety deficiency. On 10 November 2026 the company reported third-quarter results and said the resubmission remains on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The same release said Adare had completed three commercial-scale stability batches.

The shares closed at $6.78 on 9 November 2026, the day of the rebrand to AchieveRx and the new QUIT symbol, and at $6.40 on 10 November 2026, the day of the report. The last close was $6.32 on 13 November 2026. The report confirmed the timetable without lifting the price.

Bullish and bearish views on Achieve Life Sciences, Inc.

The bull case on Achieve Life Sciences, Inc. (QUIT), in brief: the timetable held at the third-quarter report. The bear case: registration batches are not reported.

Bull case

• The timetable held at the third-quarter report. On 10 November 2026 the company said the resubmission is on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The 11 August 2026 report had set the same dates.
• Adare has moved past the first batch. The 10 November 2026 release says Adare completed three commercial-scale stability batches. On 11 August 2026 the company had reported one engineering batch.
• The rejection centered on the plant. The complete response letter, received 20 June 2026, cited current Good Manufacturing Practice observations at a prior third-party facility and labeling not finished by the action date. The company said no efficacy or safety deficiencies were identified (second-quarter report, 11 August 2026).
• Cash rose in the quarter. Cash, cash equivalents and marketable securities were $201.5 million on 30 September 2026, against $187.3 million on 30 June 2026, mainly on warrant exercises (10 November 2026 release).
• Quit rates rose over a year. In the open-label ORCA-OL study, four-week continuous abstinence rose from 25.5% in weeks 9–12 to 31.2% in weeks 49–52 among 479 adults, with no new safety signals (10 November 2026 release; CHEST 2026 presentation, 21 October 2026).
• Launch staffing is in place. Benjamin Halladay became chief financial officer on 1 October 2026 and Kaitlyn Tuson became senior vice president of marketing and communications on 7 October 2026 (company releases).

Bear case

• Registration batches are not reported. The 10 November 2026 release mentions stability batches at Adare and no registration batches, and lists a possible FDA pre-approval inspection among its risk factors.
• A dispute with Sopharma AD is disclosed. The 10 November 2026 release cites the dispute without saying what it concerns.
• Overhead is rising with no revenue. Third-quarter operating expenses were $20.5 million against $14.7 million a year earlier; general and administrative expense was $14.3 million against $9.4 million. The nine-month 2026 net loss was $97.0 million (10 November 2026 release).
• Cheap stock overhangs the shares. The April 2026 placement sold 49.4 million shares at $3.635 and attached 49.5 million warrants at $3.51 (company 8-K, 16 April 2026). Warrant exercises add cash and new shares together. Director Richard Alistair Stewart sold 20,626 shares at $8.49 on 19 August 2026 (SEC Form 4).
• Generic competition shapes pricing. Cytisinicline would launch against generic varenicline, which could restrain launch pricing and payer coverage in 2027.

Price setup

The shares closed at $6.32 on 13 November 2026. That is 26.9% below the 52-week high of $8.64, reached intraday on 3 September 2026, and the 3-month change is –15.7%. The 52-week closing low was $2.65 on 27 March 2026.

The close sits below the 50-day average of $7.13 and above the 200-day average of $5.71, both as of 13 November 2026. Closes since the report were $6.40 on 10 November 2026, $6.45 on 11 November 2026, $6.29 on 12 November 2026 and $6.32 on 13 November 2026.

The market has priced in an on-time refiling but not an approval: the shares fell over three months while the company held its fourth-quarter 2026 refiling date at two successive quarterly reports. Across US stocks trading at least $5 million a day, the spread of 63-session returns was 27% in 2026 (standard deviation), so a three-month outcome for a single-catalyst name can land far from the index either way.

Catalysts ahead

• ~31 December 2026 (est.): NDA resubmission for cytisinicline naming Adare as finished-product manufacturer. The company says the refiling is on track for the fourth quarter of 2026; it is the gating step toward approval in the first half of 2027, and a slip into 2027 delays the whole timeline.
• ~30 June 2027 (est.): Potential FDA approval of cytisinicline. The company anticipates approval by the end of the second quarter of 2027; approval would allow a US launch and open the 20-trading-day window for exercising the remaining April 2026 warrants.

What would change the view

A daily close below $5.75, just above the 200-day average, which would show the market doubting the refiling timetable. The case also breaks if the resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.

The risks this note tracks, each with what would confirm it:

• The NDA resubmission slips past the fourth quarter of 2026. Confirmed by: a company update moving the refiling into 2027, or no resubmission announcement by the first quarterly report of 2027.
• Manufacturing problems at Adare delay the filing or trigger a second complete response letter. Confirmed by: disclosure of failed registration batches, missing stability work or adverse FDA inspection findings at Adare.
• The dispute with Sopharma AD, cited in the 10 November 2026 release, affects supply or rights to cytisinicline. Confirmed by: a company filing or release describing the dispute's subject, a legal claim, or a change in the licence terms.
• Placement investors and warrant holders sell into strength, or the company issues new shares. Confirmed by: form 4 or 13D/G filings showing reduced stakes by lead investors, a registered resale, or a new share offering.
• Rising overhead shortens the funding runway before launch. Confirmed by: quarterly operating expenses above the $20.5 million of the third quarter of 2026 without a matching rise in cash from warrant exercises.
• Generic varenicline restrains pricing and payer coverage at launch. Confirmed by: restrictive formulary placement or a launch price below company expectations in 2027 commercial disclosures.

What it trades with

The shares trade on company-specific regulatory news. The complete response letter, the Adare transfer and the refiling date move them more than the broad market. Reported earnings also swing with the warrants, which are carried as a liability: the second quarter included a $48.7 million non-cash warrant charge, and the third quarter included a $6.9 million non-cash gain (company releases, 11 August 2026 and 10 November 2026). Headline losses therefore say little about the cash cost of running the business.